Workflow
怡和嘉业(301367) - 2025 Q1 - 季度财报
301367BMC Medical (301367)2025-04-24 11:50

Revenue and Profit - The company's revenue for Q1 2025 reached ¥265,285,881.67, representing a 38.11% increase compared to ¥192,086,116.73 in the same period last year[5] - Net profit attributable to shareholders was ¥71,931,423.74, up 44.11% from ¥49,913,780.97 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥60,185,098.89, reflecting a 43.18% increase from ¥42,035,734.05 in the previous year[5] - Basic earnings per share increased to ¥0.8091, a rise of 44.12% compared to ¥0.5614 in the previous year[5] - The net profit for the current period is 72,924,238.36, an increase of 44.2% compared to 50,553,898.72 in the previous period[19] - The total comprehensive income for the current period is 73,143,755.67, compared to 50,540,848.17 in the previous period, marking a 44.7% increase[19] Cash Flow and Liquidity - The company's cash flow from operating activities decreased by 44.82% to ¥41,758,055.67, down from ¥75,677,651.08 in the same quarter last year[5] - The company's cash management saw a significant increase in cash and cash equivalents, rising by 69.64% to ¥889,873,477.69 from ¥524,572,179.44[9] - The cash flow from operating activities netted 41,758,055.67, a decrease of 44.7% compared to 75,677,651.08 in the previous period[22] - The cash flow from investment activities generated a net inflow of 361,637,030.28, contrasting with a net outflow of -347,230,480.53 in the previous period[22] - The cash and cash equivalents at the end of the period totaled 808,753,462.89, an increase from 396,234,366.59 at the end of the previous period[23] - The company experienced a foreign exchange impact on cash and cash equivalents amounting to 8,640,195.05, compared to 896,845.76 in the previous period[23] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥3,382,519,388.47, a slight decrease of 1.23% from ¥3,424,805,016.73 at the end of the previous year[5] - Current liabilities decreased to ¥469,262,906.71 from ¥578,626,139.33, a reduction of about 18.9%[16] - The company's total equity attributable to shareholders rose to ¥2,898,395,202.34 from ¥2,828,264,283.28, an increase of approximately 2.5%[17] Operating Costs and Expenses - The operating costs increased by 44.35% to ¥133,796,248.45, driven by the growth in revenue scale[9] - Total operating costs amounted to ¥195,415,181.05, up from ¥149,003,247.49, indicating a rise of about 31.1%[18] - Research and development expenses for the current period were ¥27,163,245.99, compared to ¥25,133,871.27 in the previous period, reflecting an increase of about 8.1%[18] Government Support and Taxation - The company received government subsidies amounting to ¥3,842,211.00, which positively impacted the financial results[6] - The company reported a significant increase in tax liabilities, with a 301.79% rise in taxes payable to ¥20,404,245.44 from ¥5,078,300.48[9] Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,118, with no preferred shareholders restoring voting rights[11] - The largest shareholder, Zhuang Zhi, holds 13.10% of shares, amounting to 11,736,608 shares[11] - The company approved a stock incentive plan for 2025, which includes management measures and related legal opinions[13] Financial Income and Borrowings - The company reported a financial income of ¥5,107,599.60, down from ¥6,710,790.93, indicating a decrease of approximately 23.9%[18] - Cash received from borrowings amounted to CNY 148.99 million, attributed to new financing loans from subsidiaries[10] - Cash paid for debt repayment reached CNY 198.8 million, primarily for the repayment of maturing financing loans by subsidiaries[10]